has been cited by the following article(s):
[1]
|
Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real‐world evidence from the medicare population
Cancer Medicine,
2021
DOI:10.1002/cam4.3855
|
|
|
[2]
|
Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real‐world evidence from the medicare population
Cancer Medicine,
2021
DOI:10.1002/cam4.3855
|
|
|